Stem definition | Drug id | CAS RN |
---|---|---|
2597 | 91161-71-6 |
Dose | Unit | Route |
---|---|---|
0.25 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 92.64 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 40 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 30, 1992 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Ageusia | 396.61 | 15.29 | 135 | 10854 | 11337 | 46663736 |
Subacute cutaneous lupus erythematosus | 186.01 | 15.29 | 50 | 10939 | 1865 | 46673208 |
Acute generalised exanthematous pustulosis | 174.19 | 15.29 | 70 | 10919 | 9335 | 46665738 |
Dysgeusia | 173.98 | 15.29 | 112 | 10877 | 40379 | 46634694 |
Rash pustular | 112.69 | 15.29 | 47 | 10942 | 6882 | 46668191 |
Pruritus | 105.10 | 15.29 | 197 | 10792 | 242155 | 46432918 |
Gamma-glutamyltransferase increased | 103.36 | 15.29 | 74 | 10915 | 31666 | 46643407 |
Cutaneous lupus erythematosus | 96.14 | 15.29 | 32 | 10957 | 2497 | 46672576 |
Erythema multiforme | 94.49 | 15.29 | 46 | 10943 | 9658 | 46665415 |
Aspartate aminotransferase increased | 94.29 | 15.29 | 104 | 10885 | 78596 | 46596477 |
Blood alkaline phosphatase increased | 86.74 | 15.29 | 73 | 10916 | 39536 | 46635537 |
Alanine aminotransferase increased | 81.21 | 15.29 | 102 | 10887 | 88349 | 46586724 |
Toxic skin eruption | 81.14 | 15.29 | 45 | 10944 | 12342 | 46662731 |
Rash | 78.77 | 15.29 | 222 | 10767 | 356290 | 46318783 |
Skin exfoliation | 72.71 | 15.29 | 61 | 10928 | 32877 | 46642196 |
Chromaturia | 68.04 | 15.29 | 43 | 10946 | 14976 | 46660097 |
Pathogen resistance | 62.85 | 15.29 | 30 | 10959 | 6030 | 46669043 |
Jaundice | 60.75 | 15.29 | 52 | 10937 | 28793 | 46646280 |
Somatic delusion | 59.49 | 15.29 | 16 | 10973 | 597 | 46674476 |
Erythema | 51.92 | 15.29 | 108 | 10881 | 142712 | 46532361 |
Anosmia | 51.78 | 15.29 | 23 | 10966 | 3921 | 46671152 |
Urticaria | 49.87 | 15.29 | 95 | 10894 | 117797 | 46557276 |
Rash erythematous | 49.26 | 15.29 | 50 | 10939 | 34300 | 46640773 |
Hepatic function abnormal | 47.36 | 15.29 | 49 | 10940 | 34372 | 46640701 |
Hepatitis | 44.58 | 15.29 | 46 | 10943 | 32169 | 46642904 |
Blister | 43.36 | 15.29 | 53 | 10936 | 44578 | 46630495 |
Scedosporium infection | 43.02 | 15.29 | 12 | 10977 | 514 | 46674559 |
Blood lactate dehydrogenase increased | 41.22 | 15.29 | 36 | 10953 | 20464 | 46654609 |
Blood bilirubin increased | 40.57 | 15.29 | 45 | 10944 | 34139 | 46640934 |
Photosensitivity reaction | 37.48 | 15.29 | 28 | 10961 | 12764 | 46662309 |
Lip swelling | 36.47 | 15.29 | 37 | 10952 | 25358 | 46649715 |
Pustular psoriasis | 35.99 | 15.29 | 18 | 10971 | 3999 | 46671074 |
Skin lesion | 34.91 | 15.29 | 37 | 10952 | 26676 | 46648397 |
Liver disorder | 32.62 | 15.29 | 42 | 10947 | 37204 | 46637869 |
Drug eruption | 32.33 | 15.29 | 32 | 10957 | 21297 | 46653776 |
Oral discomfort | 31.74 | 15.29 | 21 | 10968 | 7897 | 46667176 |
Weight decreased | 31.47 | 15.29 | 115 | 10874 | 210734 | 46464339 |
Abnormal faeces | 30.09 | 15.29 | 16 | 10973 | 4033 | 46671040 |
Drug resistance | 29.99 | 15.29 | 28 | 10961 | 17340 | 46657733 |
Dermatophytosis | 28.87 | 15.29 | 7 | 10982 | 171 | 46674902 |
Gastrointestinal motility disorder | 28.58 | 15.29 | 16 | 10973 | 4462 | 46670611 |
Rash maculo-papular | 28.53 | 15.29 | 34 | 10955 | 27840 | 46647233 |
Hepatitis cholestatic | 27.47 | 15.29 | 18 | 10971 | 6659 | 46668414 |
Urine odour abnormal | 27.06 | 15.29 | 16 | 10973 | 4946 | 46670127 |
Onychomycosis | 26.98 | 15.29 | 15 | 10974 | 4128 | 46670945 |
Rash papular | 26.63 | 15.29 | 23 | 10966 | 12875 | 46662198 |
Death | 26.53 | 15.29 | 24 | 10965 | 335524 | 46339549 |
Skin oedema | 25.74 | 15.29 | 9 | 10980 | 814 | 46674259 |
Rash pruritic | 25.66 | 15.29 | 41 | 10948 | 44174 | 46630899 |
Systemic lupus erythematosus rash | 25.39 | 15.29 | 10 | 10979 | 1262 | 46673811 |
Dermatitis exfoliative | 24.97 | 15.29 | 16 | 10973 | 5700 | 46669373 |
Cholestasis | 24.61 | 15.29 | 31 | 10958 | 26862 | 46648211 |
Tinea pedis | 24.37 | 15.29 | 10 | 10979 | 1403 | 46673670 |
Red blood cell count decreased | 24.30 | 15.29 | 34 | 10955 | 32589 | 46642484 |
Bilirubin conjugated increased | 23.91 | 15.29 | 12 | 10977 | 2686 | 46672387 |
Tinea infection | 23.76 | 15.29 | 9 | 10980 | 1023 | 46674050 |
Antinuclear antibody positive | 23.60 | 15.29 | 16 | 10973 | 6264 | 46668809 |
Hypotension | 23.14 | 15.29 | 13 | 10976 | 232576 | 46442497 |
Drug-induced liver injury | 22.83 | 15.29 | 29 | 10960 | 25339 | 46649734 |
Erythema nodosum | 22.74 | 15.29 | 13 | 10976 | 3773 | 46671300 |
Blood creatine phosphokinase increased | 22.31 | 15.29 | 30 | 10959 | 27694 | 46647379 |
Toxicity to various agents | 22.29 | 15.29 | 11 | 10978 | 211755 | 46463318 |
Rheumatoid arthritis | 21.72 | 15.29 | 15 | 10974 | 240200 | 46434873 |
Musculoskeletal discomfort | 21.13 | 15.29 | 21 | 10968 | 14035 | 46661038 |
Drug interaction | 21.00 | 15.29 | 99 | 10890 | 202995 | 46472078 |
Fungal skin infection | 20.65 | 15.29 | 12 | 10977 | 3590 | 46671483 |
Rash macular | 20.55 | 15.29 | 24 | 10965 | 19236 | 46655837 |
Pythium insidiosum infection | 19.99 | 15.29 | 3 | 10986 | 3 | 46675070 |
Decreased appetite | 19.68 | 15.29 | 94 | 10895 | 193742 | 46481331 |
Off label use | 19.02 | 15.29 | 38 | 10951 | 379803 | 46295270 |
Abortion induced | 18.60 | 15.29 | 17 | 10972 | 10243 | 46664830 |
Drug intolerance | 18.14 | 15.29 | 6 | 10983 | 147043 | 46528030 |
Liver function test abnormal | 17.84 | 15.29 | 36 | 10953 | 46451 | 46628622 |
Drug ineffective | 17.67 | 15.29 | 91 | 10898 | 677747 | 45997326 |
Face oedema | 17.40 | 15.29 | 22 | 10967 | 19131 | 46655942 |
Pityriasis rosea | 17.36 | 15.29 | 4 | 10985 | 78 | 46674995 |
Eosinophilia | 17.34 | 15.29 | 22 | 10967 | 19195 | 46655878 |
Hepatitis toxic | 17.22 | 15.29 | 10 | 10979 | 2990 | 46672083 |
Fundoscopy abnormal | 17.05 | 15.29 | 3 | 10986 | 13 | 46675060 |
Cheilitis | 17.02 | 15.29 | 11 | 10978 | 3977 | 46671096 |
Swollen tongue | 16.81 | 15.29 | 27 | 10962 | 29205 | 46645868 |
Rash papulosquamous | 16.61 | 15.29 | 4 | 10985 | 95 | 46674978 |
Dermatitis bullous | 16.53 | 15.29 | 14 | 10975 | 7629 | 46667444 |
C-reactive protein increased | 16.42 | 15.29 | 40 | 10949 | 58550 | 46616523 |
Lymphocyte stimulation test positive | 16.35 | 15.29 | 6 | 10983 | 624 | 46674449 |
Eosinophil count increased | 16.18 | 15.29 | 14 | 10975 | 7852 | 46667221 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pathogen resistance | 163.81 | 14.37 | 75 | 11512 | 8335 | 29932556 |
Aspartate aminotransferase increased | 121.98 | 14.37 | 136 | 11451 | 63286 | 29877605 |
Gamma-glutamyltransferase increased | 105.87 | 14.37 | 89 | 11498 | 29261 | 29911630 |
Alanine aminotransferase increased | 100 | 14.37 | 133 | 11454 | 74143 | 29866748 |
Ageusia | 97.90 | 14.37 | 54 | 11533 | 8899 | 29931992 |
Chromaturia | 85.57 | 14.37 | 58 | 11529 | 13807 | 29927084 |
Drug resistance | 82.98 | 14.37 | 66 | 11521 | 20067 | 29920824 |
Acute generalised exanthematous pustulosis | 81.36 | 14.37 | 42 | 11545 | 6056 | 29934835 |
Jaundice | 78.99 | 14.37 | 79 | 11508 | 32407 | 29908484 |
Blood creatine phosphokinase increased | 74.06 | 14.37 | 88 | 11499 | 43760 | 29897131 |
Blood alkaline phosphatase increased | 71.86 | 14.37 | 74 | 11513 | 31413 | 29909478 |
Onychomycosis | 64.21 | 14.37 | 26 | 11561 | 2137 | 29938754 |
Symmetrical drug-related intertriginous and flexural exanthema | 60.33 | 14.37 | 14 | 11573 | 166 | 29940725 |
Death | 55.61 | 14.37 | 35 | 11552 | 357248 | 29583643 |
Rash pustular | 51.58 | 14.37 | 29 | 11558 | 4954 | 29935937 |
Skin exfoliation | 50.23 | 14.37 | 53 | 11534 | 23119 | 29917772 |
Scedosporium infection | 49.21 | 14.37 | 16 | 11571 | 699 | 29940192 |
Liver function test abnormal | 47.17 | 14.37 | 59 | 11528 | 30891 | 29910000 |
Diaphragmatic spasm | 46.42 | 14.37 | 10 | 11577 | 82 | 29940809 |
Rash | 46.34 | 14.37 | 171 | 11416 | 191718 | 29749173 |
Faecal volume decreased | 46.00 | 14.37 | 10 | 11577 | 86 | 29940805 |
Liver disorder | 45.84 | 14.37 | 57 | 11530 | 29665 | 29911226 |
Pruritus | 45.70 | 14.37 | 124 | 11463 | 118080 | 29822811 |
Blood bilirubin increased | 43.77 | 14.37 | 62 | 11525 | 36574 | 29904317 |
Hypotension | 43.38 | 14.37 | 12 | 11575 | 200553 | 29740338 |
Blood lactate dehydrogenase increased | 40.93 | 14.37 | 45 | 11542 | 20556 | 29920335 |
Rash erythematous | 39.43 | 14.37 | 46 | 11541 | 22406 | 29918485 |
Epstein-Barr virus antibody positive | 38.02 | 14.37 | 11 | 11576 | 323 | 29940568 |
Swelling of eyelid | 37.80 | 14.37 | 11 | 11576 | 330 | 29940561 |
Cutaneous lupus erythematosus | 35.58 | 14.37 | 12 | 11575 | 588 | 29940303 |
Treatment failure | 34.69 | 14.37 | 54 | 11533 | 34625 | 29906266 |
Hepatic function abnormal | 33.47 | 14.37 | 59 | 11528 | 41886 | 29899005 |
Erythema multiforme | 32.50 | 14.37 | 26 | 11561 | 7959 | 29932932 |
Antinuclear antibody positive | 31.78 | 14.37 | 14 | 11573 | 1418 | 29939473 |
Cholestasis | 30.94 | 14.37 | 43 | 11544 | 24907 | 29915984 |
Toxicity to various agents | 30.88 | 14.37 | 15 | 11572 | 177168 | 29763723 |
Trichophytosis | 30.10 | 14.37 | 9 | 11578 | 297 | 29940594 |
Erythema nodosum | 26.76 | 14.37 | 11 | 11576 | 939 | 29939952 |
Erythema | 26.69 | 14.37 | 78 | 11509 | 77373 | 29863518 |
Dermatitis exfoliative | 25.60 | 14.37 | 22 | 11565 | 7434 | 29933457 |
Rhabdomyolysis | 24.82 | 14.37 | 67 | 11520 | 63513 | 29877378 |
Tinea pedis | 24.77 | 14.37 | 11 | 11576 | 1135 | 29939756 |
Myalgia | 24.33 | 14.37 | 75 | 11512 | 76592 | 29864299 |
Hepatic lesion | 23.94 | 14.37 | 15 | 11572 | 3121 | 29937770 |
Dysgeusia | 22.57 | 14.37 | 37 | 11550 | 24764 | 29916127 |
Erythrodermic psoriasis | 22.07 | 14.37 | 9 | 11578 | 753 | 29940138 |
Rosacea | 21.94 | 14.37 | 10 | 11577 | 1097 | 29939794 |
Blister | 21.79 | 14.37 | 33 | 11554 | 20650 | 29920241 |
Completed suicide | 21.38 | 14.37 | 6 | 11581 | 99486 | 29841405 |
Lymphocyte stimulation test positive | 20.79 | 14.37 | 9 | 11578 | 874 | 29940017 |
Hodgkin's disease | 20.32 | 14.37 | 9 | 11578 | 923 | 29939968 |
Hairy cell leukaemia | 19.98 | 14.37 | 5 | 11582 | 83 | 29940808 |
Skin warm | 19.80 | 14.37 | 11 | 11576 | 1835 | 29939056 |
Urticaria | 19.77 | 14.37 | 56 | 11531 | 54550 | 29886341 |
Tenosynovitis stenosans | 19.66 | 14.37 | 4 | 11583 | 24 | 29940867 |
Deficiency of bile secretion | 19.66 | 14.37 | 4 | 11583 | 24 | 29940867 |
Pneumonia | 19.10 | 14.37 | 66 | 11521 | 334240 | 29606651 |
Hepatitis cholestatic | 18.84 | 14.37 | 19 | 11568 | 7853 | 29933038 |
Pythium insidiosum infection | 18.50 | 14.37 | 3 | 11584 | 3 | 29940888 |
Drug-induced liver injury | 18.37 | 14.37 | 31 | 11556 | 21243 | 29919648 |
Benign breast neoplasm | 18.03 | 14.37 | 3 | 11584 | 4 | 29940887 |
Liver injury | 17.86 | 14.37 | 23 | 11564 | 12377 | 29928514 |
Chromoblastomycosis | 17.04 | 14.37 | 4 | 11583 | 50 | 29940841 |
Biliary obstruction | 16.91 | 14.37 | 11 | 11576 | 2442 | 29938449 |
Faeces pale | 16.39 | 14.37 | 9 | 11578 | 1468 | 29939423 |
Tongue discomfort | 16.24 | 14.37 | 6 | 11581 | 385 | 29940506 |
Neutrophil percentage decreased | 16.02 | 14.37 | 6 | 11581 | 400 | 29940491 |
Eyelid pain | 15.90 | 14.37 | 4 | 11583 | 68 | 29940823 |
Hepatic enzyme increased | 15.87 | 14.37 | 38 | 11549 | 33456 | 29907435 |
Off label use | 15.76 | 14.37 | 47 | 11540 | 249243 | 29691648 |
Product dispensing error | 15.56 | 14.37 | 15 | 11572 | 5874 | 29935017 |
Malaise | 15.47 | 14.37 | 114 | 11473 | 166848 | 29774043 |
Peyronie's disease | 15.43 | 14.37 | 4 | 11583 | 77 | 29940814 |
Nail discolouration | 15.39 | 14.37 | 7 | 11580 | 764 | 29940127 |
Tooth abscess | 15.35 | 14.37 | 14 | 11573 | 5112 | 29935779 |
Smooth muscle antibody positive | 15.21 | 14.37 | 3 | 11584 | 15 | 29940876 |
Vitamin E deficiency | 15.21 | 14.37 | 3 | 11584 | 15 | 29940876 |
Dermatitis | 14.82 | 14.37 | 17 | 11570 | 8125 | 29932766 |
Neuropsychiatric symptoms | 14.81 | 14.37 | 6 | 11581 | 493 | 29940398 |
Source | Code | Description |
---|---|---|
ATC | D01AE15 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Other antifungals for topical use |
ATC | D01BA02 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR SYSTEMIC USE Antifungals for systemic use |
FDA CS | M0000751 | Allylamine |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000935 | Antifungal Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
CHEBI has role | CHEBI:50183 | cytochrome p450 inhibitor |
CHEBI has role | CHEBI:59285 | squalene-2,3-epoxidase inhibitors |
CHEBI has role | CHEBI:83317 | sterol biosynthesis inhibitors |
FDA EPC | N0000175874 | Allylamine Antifungal |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Tinea capitis | indication | 5441008 | |
Tinea pedis | indication | 6020002 | DOID:12403 |
Pityriasis versicolor | indication | 56454009 | DOID:9060 |
Tinea corporis | indication | 84849002 | |
Tinea cruris | indication | 399029005 | |
Onychomycosis due to dermatophyte | indication | 402134005 | |
Onychomycosis of fingernails | indication | 403058003 | |
Onychomycosis of toenails | indication | 403059006 | |
Candidiasis of skin | off-label use | 49883006 | |
Chromoblastomycosis | off-label use | 187079000 | |
Alcoholism | contraindication | 7200002 | |
Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Breastfeeding (mother) | contraindication | 413712001 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.02 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 6.63 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.39 | DRUG MATRIX | |||||
Cytochrome P450 2D6 | Enzyme | IC50 | 6.70 | DRUG MATRIX | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 5.67 | DRUG MATRIX | |||||
Squalene monooxygenase | Enzyme | Ki | 7.52 | CHEMBL | |||||
Squalene epoxidase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Squalene monooxygenase | Unclassified | IC50 | 4.03 | CHEMBL | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 7.66 | DRUG MATRIX |
ID | Source |
---|---|
4023600 | VUID |
N0000021605 | NUI |
D02219 | KEGG_DRUG |
78628-80-5 | SECONDARY_CAS_RN |
4020792 | VANDF |
4023600 | VANDF |
C0076110 | UMLSCUI |
CHEBI:9448 | CHEBI |
CHEMBL822 | ChEMBL_ID |
CHEMBL1200832 | ChEMBL_ID |
D000077291 | MESH_DESCRIPTOR_UI |
5657 | INN_ID |
DB00857 | DRUGBANK_ID |
G7RIW8S0XP | UNII |
1549008 | PUBCHEM_CID |
235838 | RXNORM |
116863 | MMSL |
5547 | MMSL |
d04012 | MMSL |
004051 | NDDF |
004052 | NDDF |
108925005 | SNOMEDCT_US |
108927002 | SNOMEDCT_US |
373450007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
LamisilAT Jock Itch | HUMAN OTC DRUG LABEL | 1 | 0067-3999 | CREAM | 10 mg | TOPICAL | NDA | 13 sections |
LAMISILAT | HUMAN OTC DRUG LABEL | 1 | 0067-6296 | AEROSOL, SPRAY | 0.84 g | TOPICAL | NDA | 13 sections |
LAMISILAT | HUMAN OTC DRUG LABEL | 1 | 0067-6297 | AEROSOL, SPRAY | 0.84 g | TOPICAL | NDA | 13 sections |
Lamisil AT | HUMAN OTC DRUG LABEL | 1 | 0067-8100 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Lamisil ATfor Jock Itch | HUMAN OTC DRUG LABEL | 1 | 0067-8114 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Walgreens Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 0363-2080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Terbinafine Hydrochloride | HUMAN OTC DRUG LABEL | 1 | 0363-2083 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 11673-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
athletes foot | HUMAN OTC DRUG LABEL | 1 | 11673-401 | CREAM | 10 mg | TOPICAL | NDA | 7 sections |
Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 11822-0080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
terbinafine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-501 | TABLET | 250 mg | ORAL | ANDA | 20 sections |
Terbinafine | Human Prescription Drug Label | 1 | 16714-795 | TABLET | 250 mg | ORAL | ANDA | 27 sections |
Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 21130-080 | CREAM | 1 g | TOPICAL | ANDA | 13 sections |
Terbinafine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-630 | TABLET | 250 mg | ORAL | ANDA | 19 sections |
Good Neighbor Pharmacy | HUMAN OTC DRUG LABEL | 1 | 24385-524 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Kroger Antifungal | HUMAN OTC DRUG LABEL | 1 | 30142-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Terbinafine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-209 | TABLET | 250 1 | ORAL | ANDA | 26 sections |
Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 36800-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Shopko Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 37012-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 37808-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
athletes foot | HUMAN OTC DRUG LABEL | 1 | 41163-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
ShopRite | HUMAN OTC DRUG LABEL | 1 | 41190-083 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Antifungal | HUMAN OTC DRUG LABEL | 1 | 41250-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Antifungal Foot | HUMAN OTC DRUG LABEL | 1 | 41520-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
terbinafine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42043-410 | TABLET | 250 mg | ORAL | ANDA | 20 sections |
Terbinafine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-598 | TABLET | 250 mg | ORAL | ANDA | 30 sections |
Terbinafine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-906 | TABLET | 250 mg | ORAL | ANDA | 31 sections |
Terbinafine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-893 | TABLET | 250 mg | ORAL | ANDA | 31 sections |
equate Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 49035-080 | CREAM | 1 g | TOPICAL | ANDA | 14 sections |
Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 49348-790 | CREAM | 1 g | TOPICAL | ANDA | 13 sections |